Not a good buy right now for an impatient buyer: trend is bearish (SMA_200 > SMA_20 > SMA_5) with worsening momentum (MACD histogram negative and expanding).
Price (~1.07 pre-market) is sitting just above key support (S1 ~1.054); a break below support would likely trigger further downside before any sustainable rebound.
No near-term catalysts (no news this week) and weak recent operating trends reduce the probability of an immediate upside move.
Trend: Bearish structure with moving averages stacked negatively (SMA_200 > SMA_20 > SMA_5), indicating a sustained downtrend.
Momentum: MACD histogram is -0.0073 (below zero) and negatively expanding → bearish momentum is strengthening.
RSI: RSI_6 at 30.687 is near oversold territory but still described as neutral here; it suggests a possible bounce attempt, not a confirmed reversal.
Key levels:
Support: S1 1.054 (very near current 1.07), then S2 0.947.
Resistance: Pivot 1.227, then R1 1.4.
Pattern-based bias (provided): near-term weak (next week -1.32% expected), with a more favorable 1-month projection (+8.82%)—but current tape does not confirm a reliable entry today.
Positive Catalysts
holds.
Neutral/Negative Catalysts
if it fails.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 1,446,066, down -38.48% YoY (clear top-line contraction).
Net income: -5,051,084 (still a sizable loss; data shows “increased” YoY but remains deeply negative).
EPS: -4.74, down -2.07% YoY (still negative and slightly worse).
Gross margin: 27%, down -16.38% YoY (profitability pressure).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided, so recent Wall Street upgrades/downgrades and pros/cons consensus cannot be verified from the dataset.
From the available data alone, the primary “cons” would be shrinking revenue and declining margin plus a bearish chart; no clear “pro” catalyst from coverage is visible here.
Politicians/Congress: No recent congress trading data available (no evidence of influential buying/selling in the last 90 days).
Wall Street analysts forecast BIAF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIAF is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast BIAF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIAF is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Buy
Hold
Sell
0
Current: 0.750
Low
0
Averages
0
High
0
0
Current: 0.750
Low
0
Averages
0
High
0
Maxim Group
Anthony Vendetti
Strong Buy
to
Hold
Downgrades
n/a
AI Analysis
2025-04-01
Reason
Maxim Group
Anthony Vendetti
Price Target
n/a
AI Analysis
2025-04-01
Downgrades
Strong Buy
to
Hold
Reason
Maxim downgraded BioAffinity Technologies to Hold from Buy.
